{"id":27992,"date":"2026-01-13T16:21:12","date_gmt":"2026-01-13T23:21:12","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27992"},"modified":"2026-01-13T16:21:14","modified_gmt":"2026-01-13T23:21:14","slug":"ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/","title":{"rendered":"\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7ee7\u53d1\u6027\u514d\u75ab\u6291\u5236\uff1a\u57fa\u4e8e\u6700\u65b0\u8bc1\u636e\u7684\u5173\u952e\u89c1\u89e3"},"content":{"rendered":"\n<p>IVIG for hematologic malignancy-associated secondary immunosuppression may be an option when patients have severe or recurrent infections. Discover how IVIG is administered and find answers to the most common questions.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-903e9cf67ca3e9ee75c3d68c399fb266\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tTalk With a Copay Assistance Specialist\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Highlights\" >Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#What_Is_Hematologic_Malignancy-Associated_Secondary_Immunosuppression\" >What Is Hematologic Malignancy-Associated Secondary Immunosuppression?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Hematologic_Malignancy\" >Hematologic Malignancy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Secondary_Immunosuppression\" >Secondary Immunosuppression<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_What_We_Know_So_Far\" >IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: What We Know So Far<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Treatment_Considerations_and_Dosing\" >Treatment Considerations and Dosing<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Step_1_Measuring_IgG_Levels\" >Step 1: Measuring IgG Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Step_2_Starting_IVIG_Therapy\" >Step 2: Starting IVIG Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Step_3_IVIG_Dosing\" >Step 3: IVIG Dosing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_Special_Considerations\" >IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Special Considerations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_Can_A_Patient_Switch_to_Subcutaneous_Immune_Globulin_SCIG\" >IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Can A Patient Switch to Subcutaneous Immune Globulin (SCIG)?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Highlights\"><\/span>Highlights<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Hematologic malignancy-associated secondary immunosuppression means a weakened immune system caused by hematologic malignancies or their treatments.\u00a0<\/li>\n\n\n\n<li>IVIG is widely used to prevent recurrent and severe infections in patients with hematologic malignancies.\u00a0<\/li>\n\n\n\n<li>A patient may switch from <a href=\"https:\/\/ameripharmaspecialty.com\/ivig\/ivig\/\">IVIG<\/a> to <a href=\"https:\/\/ameripharmaspecialty.com\/ivig\/what-is-scig\/\">SCIG<\/a> in certain situations.\u00a0<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Hematologic_Malignancy-Associated_Secondary_Immunosuppression\"><\/span>What Is Hematologic Malignancy-Associated Secondary Immunosuppression?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Let\u2019s first break down the term \u201chematologic malignancy-associated secondary immunosuppression.\u201d&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hematologic_Malignancy\"><\/span>Hematologic Malignancy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>These cancers originate in the bone marrow or the cells of the immune system. The three main groups of hematologic malignancy are:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Leukemia<\/strong>: Leukemia occurs when the bone marrow produces abnormally high amounts of white blood cells.\u00a0<\/li>\n\n\n\n<li><strong>Lymphoma<\/strong>: Lymphoma originates in the part of the immune system called the lymphatic system. Lymphoma affects white blood cells known as lymphocytes.\u00a0<\/li>\n\n\n\n<li><strong>Multiple myeloma<\/strong>: This is a rare cancer that causes an overgrowth of specialized white blood cells called plasma cells.\u00a0<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Secondary_Immunosuppression\"><\/span>Secondary Immunosuppression<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Secondary immunosuppression refers to a weakened immune system due to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Disorders of blood or bone marrow<\/li>\n\n\n\n<li>Medications<\/li>\n\n\n\n<li>Cancer treatments<\/li>\n\n\n\n<li>Certain cancers<\/li>\n\n\n\n<li>Malnutrition\u00a0<\/li>\n\n\n\n<li>Infectious diseases<\/li>\n<\/ul>\n\n\n\n<p>Hematologic malignancy-associated secondary immunosuppression occurs when hematologic malignancies or their treatments cause a weakened immune system. A weakened immune system puts patients at a higher risk of getting recurrent or severe infections.&nbsp;<\/p>\n\n\n\n<p>IVIG (intravenous immunoglobulin) is one of the treatment options for hematologic malignancy-associated immunosuppression. Other management options include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Preventive antibiotic treatment and vaccination<\/li>\n\n\n\n<li>Reduced immunosuppression<\/li>\n\n\n\n<li>Treatment of the underlying condition<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-edc8834cc18f0f4b69e465c2a07a72db\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tDo You Qualify for $0 Copay?\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tTalk to a Specialist to Find Out\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Schedule a Consultation<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_What_We_Know_So_Far\"><\/span>IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: What We Know So Far<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"320\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse.jpg\" alt=\"Smiling IVIG nurse standing next to an IV pole\" class=\"wp-image-27995\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-300x229.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-16x12.jpg 16w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-86x66.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-167x127.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-280x213.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-nurse-370x282.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>IVIG is widely used to help reduce the risk of severe infections in patients with hematologic malignancies. In these patients, IVIG can prevent recurrent and severe infections [<a href=\"https:\/\/smw.ch\/index.php\/smw\/article\/view\/3559\">1<\/a>]. A healthcare provider may consider IVIG for hematologic malignancy-associated secondary immunosuppression when [<a href=\"https:\/\/www.secondaryimmunodeficiency.com\/immunoglobulin-therapy\/\">2<\/a>,<a href=\"https:\/\/www.frontiersin.org\/journals\/hematology\/articles\/10.3389\/frhem.2024.1347708\/full\">3<\/a>]:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients have severe or recurrent infections<\/li>\n\n\n\n<li>Antibiotics are ineffective<\/li>\n\n\n\n<li>IgG level is less than 4g\/l<\/li>\n\n\n\n<li>Patient is receiving CAR-T Cell therapy<\/li>\n<\/ul>\n\n\n\n<p>Further Reading: <a href=\"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-car-t-therapy-related-hypogammaglobulinemia-uses-benefits-dosage-and-more\/\">IVIG for CAR-T Therapy-Related Hypogammaglobulinemia: Uses, Benefits, Dosage, and More<\/a><\/p>\n\n\n\n<p>However, the use of IVIG for hematologic malignancy-associated secondary immunosuppression is still not clear because:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The benefits of IVIG for hematologic malignancy-associated secondary immunosuppression come from small clinical trials; robust evidence from large controlled trials is lacking.\u00a0<\/li>\n\n\n\n<li>There are no specific clinical treatment guidelines on the use of IVIG in this patient population.<\/li>\n<\/ul>\n\n\n\n<p>Due to cost and limited supply of IVIG, it is typically recommended for therapy to be individualized based on the patient&#8217;s condition and type of cancer therapy.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Treatment_Considerations_and_Dosing\"><\/span>Treatment Considerations and Dosing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Administering IVIG for hematologic malignancy-associated secondary immunosuppression involves several steps.&nbsp;<\/p>\n\n\n\n<p>First, a healthcare provider will measure the IgG levels before or during cancer treatment. Second, they will determine when to start IVIG therapy, which typically relies on the IgG levels. Lastly, they will determine the dose based on the body weight.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Step_1_Measuring_IgG_Levels\"><\/span>Step 1: Measuring IgG Levels<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to the European expert consensus, in patients with hematologic malignancies [<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/pdfdirect\/10.1111\/ejh.13580?utm_source=consensus\">4<\/a>]:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Measuring IgG levels before starting cancer treatment can help estimate the patient\u2019s risk of developing infections.\u00a0<\/li>\n\n\n\n<li>A healthcare provider may also measure Ig levels during routine visits if the patient has already started cancer treatment.\u00a0<\/li>\n<\/ul>\n\n\n\n<p>For patients younger than 21 years, a healthcare provider will interpret the IgG levels based on <a href=\"https:\/\/ameripharmaspecialty.com\/ivig\/what-are-the-normal-igg-levels-by-age\/\">what\u2019s considered normal for their specific age<\/a>.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-b08802ea47907792254aa87ee4de19cb\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tGet Financial Assistance\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Step_2_Starting_IVIG_Therapy\"><\/span>Step 2: Starting IVIG Therapy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The ideal candidates for IVIG for hematologic malignancy-associated secondary immunosuppression are those with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IgG levels less than 4 g\/l who have received antimicrobial therapy. IVIG should be started during or after a single severe infection or recurrent infection.\u00a0<\/li>\n\n\n\n<li>IgG levels less than 4 g\/l who have severe or recurrent infections even after they have received antimicrobial therapy.\u00a0<\/li>\n<\/ul>\n\n\n\n<p>While not all experts agree, patients with IgG levels between 4 g\/l and 6 g\/l who have severe or recurrent infections even after they have received antimicrobial therapy may also receive IVIG treatment.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Step_3_IVIG_Dosing\"><\/span>Step 3: IVIG Dosing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>IVIG dose depends on body weight. If the patient is obese, dosage adjustment according to the ideal body weight specific to the patient is necessary.<\/p>\n\n\n\n<p>The dosing regimen of IVIG for hematologic malignancy-associated secondary immunosuppression is as follows [<a href=\"https:\/\/www.frontiersin.org\/journals\/hematology\/articles\/10.3389\/frhem.2024.1347708\/full\">3<\/a>]:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The starting dose of IVIG is 0.4 g\/kg body weight every 3 to 4 weeks.\u00a0<\/li>\n\n\n\n<li>The maintenance dose of IVIG is 0.4 to 0.8 g\/kg body weight every 3 to 4 weeks.\u00a0<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_Special_Considerations\"><\/span>IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Special Considerations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>When starting IVIG therapy, a healthcare provider may consider stopping antimicrobial treatment if the infection is under control.\u00a0<\/li>\n\n\n\n<li>If the patient doesn\u2019t have an infection for a significant period of time (typically 6 months), a healthcare provider may stop IVIG therapy.\u00a0<\/li>\n\n\n\n<li>Patients who no longer use IVIG should get their IgG levels tested during routine visits.\u00a0<\/li>\n\n\n\n<li>Should severe or persistent infections recur in patients who no longer use IVIG, IVIG treatment can be restarted.\u00a0<\/li>\n\n\n\n<li>IVIG typically causes mild infusion-related reactions, such as headache, nausea, and muscle aches.\u00a0<\/li>\n\n\n\n<li>Rare but severe side effects include severe allergic reactions, kidney failure, and rupture of red blood cells. A healthcare provider will closely monitor patients during IVIG therapy if they have risk factors for these serious side effects.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IVIG_for_Hematologic_Malignancy-Associated_Secondary_Immunosuppression_Can_A_Patient_Switch_to_Subcutaneous_Immune_Globulin_SCIG\"><\/span>IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Can A Patient Switch to Subcutaneous Immune Globulin (SCIG)?&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A patient can switch to <a href=\"https:\/\/ameripharmaspecialty.com\/ivig\/what-is-scig\/\">SCIG<\/a> after discussing the potential benefits and risks with their healthcare provider. The major benefit is that they can self-administer SCIG at home after proper training. SCIG typically also has fewer side effects than IVIG. They may choose to switch to SCIG if:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>They are ready to take charge of their health.<\/li>\n\n\n\n<li>Other forms of treatment fail to provide adequate IgG levels.<\/li>\n\n\n\n<li>Specific immunoglobulin formulations are unavailable.<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-0c3345e3395f1c8801db99774b749503\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tGet Copay Assistance Now\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Get Started<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span>Frequently Asked Questions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">What hematologic malignancy is associated with secondary immunosuppression?<\/h4>\n\n\n\n<p>Chronic lymphocytic leukemia and multiple myeloma are often associated with secondary immunosuppression.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Which type of virus has been associated with hematologic malignancies?<\/h4>\n\n\n\n<p>Viruses associated with hematologic malignancies include HIV, Epstein\u2013Barr virus (EBV), and Kaposi sarcoma\u2013associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">What is the most common cause of secondary immunodeficiency?<\/h4>\n\n\n\n<p>The most common causes of secondary immunodeficiency are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Blood or bone marrow disorders<\/li>\n\n\n\n<li>Cancer treatments<\/li>\n\n\n\n<li>Certain cancers<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u5bf9\u4e8e\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7684\u7ee7\u53d1\u6027\u514d\u75ab\u6291\u5236\uff0c\u5f53\u60a3\u8005\u51fa\u73b0\u4e25\u91cd\u6216\u53cd\u590d\u611f\u67d3\u65f6\uff0c\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\uff08IVIG\uff09\u53ef\u80fd\u662f\u4e00\u79cd\u6cbb\u7597\u9009\u62e9\u3002\u4e86\u89e3 IVIG \u7684\u7ed9\u836f\u65b9\u5f0f\uff0c\u5e76\u627e\u5230\u5e38\u89c1\u95ee\u9898\u7684\u7b54\u6848\u3002.\u00a0<\/p>","protected":false},"author":26,"featured_media":27993,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[32],"class_list":["post-27992","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-robert-hakim"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence<\/title>\n<meta name=\"description\" content=\"Learn when IVIG is used for hematologic malignancy\u2013related immunosuppression, including benefits, dosing, risks, and when SCIG may be an option.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence\" \/>\n<meta property=\"og:description\" content=\"Learn when IVIG is used for hematologic malignancy\u2013related immunosuppression, including benefits, dosing, risks, and when SCIG may be an option.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T23:21:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T23:21:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Robert Hakim, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Robert Hakim, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/\"},\"author\":{\"name\":\"Dr. Robert Hakim, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\"},\"headline\":\"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence\",\"datePublished\":\"2026-01-13T23:21:12+00:00\",\"dateModified\":\"2026-01-13T23:21:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/\"},\"wordCount\":1037,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ivig.jpg\",\"keywords\":[\"Dr. Robert Hakim\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/\",\"name\":\"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ivig.jpg\",\"datePublished\":\"2026-01-13T23:21:12+00:00\",\"dateModified\":\"2026-01-13T23:21:14+00:00\",\"description\":\"Learn when IVIG is used for hematologic malignancy\u2013related immunosuppression, including benefits, dosing, risks, and when SCIG may be an option.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ivig.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ivig.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Patient receiving IVIG for hematologic malignancy-associated secondary immunosuppression\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\",\"name\":\"Dr. Robert Hakim, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"caption\":\"Dr. Robert Hakim, PharmD\"},\"description\":\"Dr. Robert Chad Hakim, PharmD, was born and raised in Northridge, CA. He received his pharmacy degree from the University of Wisconsin-Madison School of Pharmacy. The most rewarding part of his job is taking initiative to advance clinical programs that maximize impact on patient care. He has a board certification in critical care (BCCCP), and his areas of expertise are critical care, drug information, general medicine, and cardiology. In his free time, he enjoys traveling.\u00a0\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/author\\\/robert-hakim\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7ee7\u53d1\u6027\u514d\u75ab\u6291\u5236\uff1a\u57fa\u4e8e\u6700\u65b0\u8bc1\u636e\u7684\u5173\u952e\u89c1\u89e3","description":"\u4e86\u89e3\u4f55\u65f6\u4f7f\u7528 IVIG \u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7684\u514d\u75ab\u6291\u5236\uff0c\u5305\u62ec\u76ca\u5904\u3001\u5242\u91cf\u3001\u98ce\u9669\uff0c\u4ee5\u53ca\u4f55\u65f6\u53ef\u4ee5\u4f7f\u7528 SCIG \u6cbb\u7597\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/","og_locale":"zh_CN","og_type":"article","og_title":"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence","og_description":"Learn when IVIG is used for hematologic malignancy\u2013related immunosuppression, including benefits, dosing, risks, and when SCIG may be an option.","og_url":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2026-01-13T23:21:12+00:00","article_modified_time":"2026-01-13T23:21:14+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg","type":"image\/jpeg"}],"author":"Dr. Robert Hakim, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Robert Hakim, PharmD","Est. reading time":"5 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/"},"author":{"name":"Dr. Robert Hakim, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759"},"headline":"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence","datePublished":"2026-01-13T23:21:12+00:00","dateModified":"2026-01-13T23:21:14+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/"},"wordCount":1037,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg","keywords":["Dr. Robert Hakim"],"articleSection":["IVIG"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/","name":"\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7ee7\u53d1\u6027\u514d\u75ab\u6291\u5236\uff1a\u57fa\u4e8e\u6700\u65b0\u8bc1\u636e\u7684\u5173\u952e\u89c1\u89e3","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg","datePublished":"2026-01-13T23:21:12+00:00","dateModified":"2026-01-13T23:21:14+00:00","description":"\u4e86\u89e3\u4f55\u65f6\u4f7f\u7528 IVIG \u6cbb\u7597\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u76f8\u5173\u7684\u514d\u75ab\u6291\u5236\uff0c\u5305\u62ec\u76ca\u5904\u3001\u5242\u91cf\u3001\u98ce\u9669\uff0c\u4ee5\u53ca\u4f55\u65f6\u53ef\u4ee5\u4f7f\u7528 SCIG \u6cbb\u7597\u3002.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg","width":1280,"height":853,"caption":"Patient receiving IVIG for hematologic malignancy-associated secondary immunosuppression"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-hematologic-malignancy-associated-secondary-immunosuppression-key-insights-based-on-the-latest-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Key Insights, Based on the Latest Evidence"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"AmeriPharma\u00ae \u4e13\u4e1a\u62a4\u7406","description":"AmeriPharma \u7684\u4e13\u4e1a\u62a4\u7406","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"\u7f8e\u56fd\u5236\u836f\u4e13\u4e1a\u62a4\u7406","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759","name":"Robert Hakim\u535a\u58eb\uff0c\u836f\u5b66\u535a\u58eb","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","caption":"Dr. Robert Hakim, PharmD"},"description":"Robert Chad Hakim \u535a\u58eb\uff0c\u836f\u5b66\u535a\u58eb\uff0c\u5728\u52a0\u5dde\u5317\u5cad\u51fa\u751f\u957f\u5927\u3002\u4ed6\u6bd5\u4e1a\u4e8e\u5a01\u65af\u5eb7\u661f\u5927\u5b66\u9ea6\u8fea\u900a\u5206\u6821\u836f\u5b66\u9662\uff0c\u83b7\u5f97\u836f\u5b66\u5b66\u4f4d\u3002\u5de5\u4f5c\u4e2d\u6700\u8ba9\u4ed6\u611f\u5230\u81ea\u8c6a\u7684\u662f\u79ef\u6781\u63a8\u8fdb\u4e34\u5e8a\u9879\u76ee\uff0c\u4ece\u800c\u6700\u5927\u9650\u5ea6\u5730\u63d0\u5347\u60a3\u8005\u62a4\u7406\u7684\u6548\u679c\u3002\u4ed6\u62e5\u6709\u91cd\u75c7\u76d1\u62a4\u59d4\u5458\u4f1a\u8ba4\u8bc1 (BCCCP)\uff0c\u4e13\u4e1a\u9886\u57df\u5305\u62ec\u91cd\u75c7\u76d1\u62a4\u3001\u836f\u7269\u4fe1\u606f\u3001\u5168\u79d1\u533b\u5b66\u548c\u5fc3\u810f\u75c5\u5b66\u3002\u95f2\u6687\u65f6\uff0c\u4ed6\u559c\u6b22\u65c5\u884c\u3002\u00a0","url":"https:\/\/ameripharmaspecialty.com\/zh\/author\/robert-hakim\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/zh\/author\/robert-hakim\/"},"uagb_comment_info":0,"uagb_excerpt":"IVIG for hematologic malignancy-associated secondary immunosuppression may be an option when patients have severe or recurrent infections. Discover how IVIG is administered and find answers to the most common questions.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/01\/ivig.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/zh\/author\/robert-hakim\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/zh\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"IVIG for hematologic malignancy-associated secondary immunosuppression may be an option when patients have severe or recurrent infections. Discover how IVIG is administered and find answers to the most common questions.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/posts\/27992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/comments?post=27992"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/posts\/27992\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/media\/27993"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/media?parent=27992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/categories?post=27992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/zh\/wp-json\/wp\/v2\/tags?post=27992"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}